BioPharma, Pharma

FDA Approval for Sanofi Drug Marks an Important First in Rare Disease

Sanofi’s Infilbray is now approved for treating Gaucher disease type 3. The brain-penetrating small molecule is the first FDA-approved therapy for the neurological symptoms of this rare enzyme deficiency.

The cognitive and movement problems caused by a rare inherited disease now have their first FDA-approved therapy, a Sanofi drug able to cross the blood-brain barrier to address the source of the neurological symptoms.

The Wednesday regulatory decision covers the treatment of Gaucher disease type 3 in adults as well as children who weigh at least 15 kg (about 33 pounds). Known in development as venglustat, Sanofi will commercialize its new product under the brand name Infilbray.

In Gaucher, mutations in the GBA1 gene lead to deficiency of glucocerebrosidase. Without enough of this enzyme, fatty molecules called glycosphingolipids build up in organs of the body. Gaucher is classified into three types. In type 3, the fatty accumulation in the central nervous system leads to dementia and loss of muscle control. Patients with type 3 Gaucher also experience problems in organs throughout the body, such as liver and spleen enlargement. Infilibray is a small molecule designed to block an enzyme key to the synthesis of glycosphingolipids.

presented by

FDA approval of Infilbray was based on the results of a Phase 3 test that enrolled adults and pediatric patients age 12 and older with Gaucher type 3. These patients had achieved systemic disease stabilization with prior enzyme replacement therapy. In the trial, daily doses of the oral study drug were compared to intravenous enzyme replacement therapy administered every two weeks. At one year, results for Infilbray showed statistically significant improvement according to a test that assessed multiple neurological measures.

The most common adverse effects reported in the trial included diarrhea, an enlarged spleen, and nausea. The Infilbray label also notes that the drug may increase the risk of suicidal thoughts and behavior.

Sanofi already has a strong presence in Gaucher through the enzyme replacement therapy Cerezyme, which competes with enzyme replacement therapies from Takeda Pharmaceutical and Pfizer — all three products are approved for Gaucher type 1. Earlier this year, Cerezyme expanded its label to include treatment of the non-neurological symptoms of Gaucher type 3 in adults, a regulatory decision that came nearly 30 years after the therapy was approved in this indication in Europe.

“We have been able to treat the systemic manifestations of type 3 Gaucher disease, while the neurological manifestations remained beyond the reach of available therapies,” Dr. Pramod Mistry, director of the Yale Lysosomal Disease Center and Gaucher Disease Treatment Center, said in Sanofi’s approval announcement. “The availability of a medicine capable of addressing the neurological manifestations of this devastating disorder represents a major milestone for patients, families, and the global type 3 Gaucher disease community.”

presented by

Sanofi also sells Cerdelga, an oral drug approved in 2014 for treating adults with type 1. Both Cerezyme and Cerdelga came from Genzyme, which Sanofi acquired in 2011. For 2025, Sanofi reported the two products generated more than €1 billion (about $1.1 billion) in global sales. Infilbray, which also came from Genzyme, gives Sanofi a third product for its Gaucher franchise.

Not all of Sanofi’s research efforts with Infilibray have been successful. Last year, the company reported the drug did not meet the goals of a Phase 3 test in Fabry disease, another rare enzyme deficiency. For type 3 Gaucher, Sanofi said the drug is still under regulatory review in Europe and Japan. The company also plans regulatory submissions in other markets in the coming year.

Photo: Nathan Laine/Bloomberg, via Getty Images